Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit
Avant Technologies (OTCQB: AVAI) and its partner Ainnova Tech are expanding their joint venture, Ai-nova Acquisition Corp (AAC), across Latin America following Ainnova's participation in the 2025 Healthcare Innovation Summit in Mexico City. The expansion includes commercial pilots in Chile and Dominican Republic hospitals, focusing on demonstrating cost reduction in preventive diagnostics and improved healthcare efficiency.
The pilots utilize Ainnova's Vision AI platform for real-time health risk identification, enabling specialty care referrals. The joint venture plans to deploy an automated retinal imaging device integrated with AI to screen for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images and basic health data.
AAC holds global licensing rights for Ainnova's technology portfolio. The companies are pursuing regulatory approvals in Brazil through MDSAP certification for ANVISA requirements, while simultaneously preparing for FDA clinical trials in the United States.
Avant Technologies (OTCQB: AVAI) e il suo partner Ainnova Tech stanno ampliando la loro joint venture, Ai-nova Acquisition Corp (AAC), in tutta l'America Latina dopo la partecipazione di Ainnova al 2025 Healthcare Innovation Summit a Città del Messico. L'espansione comprende progetti pilota commerciali negli ospedali di Cile e Repubblica Dominicana, con l'obiettivo di dimostrare la riduzione dei costi nella diagnostica preventiva e un miglioramento dell'efficienza sanitaria.
I progetti pilota utilizzano la piattaforma Vision AI di Ainnova per l'identificazione in tempo reale dei rischi per la salute, favorendo i riferimenti alle cure specialistiche. La joint venture prevede di implementare un dispositivo automatizzato per l'imaging retinico integrato con l'intelligenza artificiale per lo screening di malattie cardiovascolari, diabete di tipo 2, fibrosi epatica e malattia renale cronica, utilizzando immagini retiniche e dati sanitari di base.
AAC detiene i diritti di licenza globale per il portafoglio tecnologico di Ainnova. Le aziende stanno perseguendo le approvazioni regolatorie in Brasile tramite la certificazione MDSAP per i requisiti ANVISA, mentre si preparano parallelamente ai trial clinici FDA negli Stati Uniti.
Avant Technologies (OTCQB: AVAI) y su socio Ainnova Tech están ampliando su empresa conjunta, Ai-nova Acquisition Corp (AAC), en toda América Latina tras la participación de Ainnova en la Cumbre de Innovación en Salud 2025 en Ciudad de México. La expansión incluye pilotos comerciales en hospitales de Chile y República Dominicana, centrados en demostrar la reducción de costos en diagnósticos preventivos y una mayor eficiencia en la atención médica.
Los pilotos utilizan la plataforma Vision AI de Ainnova para la identificación en tiempo real de riesgos para la salud, facilitando las derivaciones a atención especializada. La empresa conjunta planea desplegar un dispositivo automatizado de imagen retiniana integrado con IA para detectar enfermedades cardiovasculares, diabetes tipo 2, fibrosis hepática y enfermedad renal crónica mediante imágenes retinianas y datos básicos de salud.
AAC posee los derechos de licencia global para el portafolio tecnológico de Ainnova. Las compañías buscan aprobaciones regulatorias en Brasil mediante la certificación MDSAP para cumplir con los requisitos de ANVISA, mientras se preparan simultáneamente para ensayos clínicos de la FDA en Estados Unidos.
Avant Technologies (OTCQB: AVAI)와 그 파트너 Ainnova Tech는 2025년 멕시코시티에서 열린 헬스케어 혁신 서밋에 Ainnova가 참여한 후 라틴 아메리카 전역으로 합작 투자 회사 Ai-nova Acquisition Corp (AAC)를 확장하고 있습니다. 이번 확장에는 칠레와 도미니카공화국 병원에서의 상업적 시범 사업이 포함되며, 예방 진단 비용 절감과 의료 효율성 향상을 목표로 합니다.
이 시범 사업들은 Ainnova의 Vision AI 플랫폼을 활용하여 실시간 건강 위험을 식별하고 전문 치료 의뢰를 가능하게 합니다. 합작 투자는 AI가 통합된 자동 망막 영상 장치를 배치하여 망막 이미지와 기본 건강 데이터를 사용해 심혈관 질환, 제2형 당뇨병, 간 섬유증, 만성 신장 질환을 선별할 계획입니다.
AAC는 Ainnova의 기술 포트폴리오에 대한 글로벌 라이선스 권리를 보유하고 있습니다. 두 회사는 브라질에서 ANVISA 요구사항을 위한 MDSAP 인증을 통해 규제 승인을 추진하는 한편, 미국 FDA 임상 시험 준비도 병행하고 있습니다.
Avant Technologies (OTCQB : AVAI) et son partenaire Ainnova Tech étendent leur coentreprise, Ai-nova Acquisition Corp (AAC), à travers l'Amérique latine suite à la participation d'Ainnova au Sommet de l'Innovation en Santé 2025 à Mexico. Cette expansion comprend des projets pilotes commerciaux dans des hôpitaux au Chili et en République dominicaine, axés sur la démonstration de la réduction des coûts dans le diagnostic préventif et l'amélioration de l'efficacité des soins de santé.
Les projets pilotes utilisent la plateforme Vision AI d'Ainnova pour l'identification en temps réel des risques pour la santé, facilitant les orientations vers des soins spécialisés. La coentreprise prévoit de déployer un dispositif automatisé d'imagerie rétinienne intégré à l'IA pour dépister les maladies cardiovasculaires, le diabète de type 2, la fibrose hépatique et la maladie rénale chronique à partir d'images rétiniennes et de données de santé de base.
AAC détient les droits de licence mondiaux pour le portefeuille technologique d'Ainnova. Les entreprises poursuivent les approbations réglementaires au Brésil via la certification MDSAP pour répondre aux exigences de l'ANVISA, tout en se préparant simultanément aux essais cliniques de la FDA aux États-Unis.
Avant Technologies (OTCQB: AVAI) und sein Partner Ainnova Tech erweitern ihr Joint Venture Ai-nova Acquisition Corp (AAC) in ganz Lateinamerika, nachdem Ainnova am Healthcare Innovation Summit 2025 in Mexiko-Stadt teilgenommen hat. Die Expansion umfasst kommerzielle Pilotprojekte in Krankenhäusern in Chile und der Dominikanischen Republik, mit dem Fokus auf Kostensenkungen bei präventiven Diagnosen und verbesserter Effizienz im Gesundheitswesen.
Die Pilotprojekte nutzen die Vision AI Plattform von Ainnova zur Echtzeit-Erkennung von Gesundheitsrisiken und ermöglichen Überweisungen zu Fachärzten. Das Joint Venture plant den Einsatz eines automatisierten retinalen Bildgebungsgeräts, das mit KI integriert ist, um Herz-Kreislauf-Erkrankungen, Typ-2-Diabetes, Leberfibrose und chronische Nierenerkrankungen anhand von Netzhautbildern und Basisgesundheitsdaten zu screenen.
AAC hält die globalen Lizenzrechte für das Technologieportfolio von Ainnova. Die Unternehmen streben regulatorische Zulassungen in Brasilien über die MDSAP-Zertifizierung für ANVISA-Anforderungen an und bereiten gleichzeitig klinische Studien der FDA in den USA vor.
- Global expansion into new markets (Chile, Dominican Republic, Brazil, US)
- Proprietary AI technology for multiple disease detection
- Strategic positioning in markets with existing reimbursement codes
- Global licensing rights secured through joint venture
- Pending regulatory approvals in major markets (FDA, ANVISA)
- Commercial pilots still in early stages
- Technology effectiveness not yet proven in clinical trials
Ainnova has initiated its first commercial pilots in both
The pilot programs leverage Ainnova's proprietary Vision AI platform to identify health risks in real time, which enable seamless referrals for specialty care or further diagnostic tests when a positive risk is detected. The broader vision for the joint venture involves deploying an automated, low-cost retinal imaging device integrated with its AI-driven platform to deliver comprehensive preventive risk screening. From just two retinal images, blood pressure and some lab test information, the system will assess risks for: cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).
The message that Ainnova's CEO, Vinicio Vargas, continues to convey to audiences around the world is that this accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years.
Avant has partnered with Ainnova to form AAC so the two companies can advance and commercialize Ainnova's technology portfolio worldwide. AAC has the global licensing rights for the portfolio, including its Vision AI platform and its versatile retinal cameras.
Avant and Ainnova have identified
At the same time, Ainnova is advancing its regulatory roadmap for the U. S. The objective is to begin clinical trials in the coming months to obtain FDA approval and commercialize its technology in the U.S.—initially targeting markets where reimbursement codes for diabetic retinopathy are already approved.
About Ainnova Tech, Inc.
Ainnova is a
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc. info@avanttechnologies.com
Logo - https://mma.prnewswire.com/media/2370694/5271367/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-jv-partner-ainnova-accelerate-expansion-across-latin-america-following-key-role-at-healthcare-innovation-summit-302430278.html
SOURCE Avant Technologies Inc.
FAQ
What is the purpose of Avant Technologies (AVAI) and Ainnova's commercial pilots in Latin America?
What health conditions can Ainnova's Vision AI platform detect through retinal screening?
What are AVAI's expansion plans for Brazil and the United States in 2025?
What technology rights does Ai-nova Acquisition Corp (AAC) hold from the AVAI-Ainnova partnership?
